Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
NGM Biopharmaceuticals, Inc
The study will compare multiple doses of aldafermin against placebo in a compensated NASH cirrhosis population for 48 weeks of treatment.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Liver biopsy consistent with NASH cirrhosis.
2. Compensated cirrhosis due to NASH.
You may not be if
1. Other causes of liver disease including but not limited to alcoholic liver disease, hepatitis B, hepatitis C, autoimmune disorders, primary biliary cirrhosis, drug-induced hepatotoxicity, Wilson's disease, hemochromatosis, and alpha-1-anti-trypsin definition based on medical history and/or centralized read of liver histology.
2. Evidence of drug induced steatohepatitis secondary to amiodarone, corticosteroids, estrogens, methotrexate, tetracycline, or other medications known to cause hepatic steatosis.
3. History of hepatic decompensation including variceal bleeding, ascites, or hepatic encephalopathy.
4. Model of end stage liver disease (MELD) score \>12.
Clareo Health | Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
